DUBLIN, March 25, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/skgh5l/investigation) has announced the addition of the "Investigation Report on China Telmisartan Market" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
According to statistics from WHO, one-third of the world's adults have high blood pressure. Death toll of this disease equals to half of the total number caused by stroke and heart attack.
Angiotensin II receptor antagonist (ABR) is an important product among various antihypertensive drugs. Telmisartan was firstly developed by Boehringer Ingelheim and approved to the U.S. market for the first time in 1999 with the trade name ""Micardis"". It is a once-daily oral medication for the treatment of essential hypertension. In the same year, telmisartan was jointly sold as ""Micardis"" by Boehringer Ingelheim and ""Pritor"" by Glaxo Wellcome in Germany. It was approved to market in December 1999 in Philippines. In 2000, it was approved to market in Australia, Belgium and Britain. Glaxo Wellcome owns the marketing right worldwide except in Japan and the U.S. The company is also developing compound preparation of telmisartan and other hypertension drugs. Abbott Laboratories holds the sales license of this product in the United States. At the end of 2000, Boehringer Ingelheim introduced raw material and preparation of telmisartan into Chinese market. Several telmisartan generic drugs have also been approved to Chinese market in succession since 2004.
Statistics shows that incidence of hypertension among Chinese people aged 15 and above is 24%. There are more than 260 million hypertension patients in the country, with at least one hypertension patient among 5 adults. The prevention and cure for hypertension in China is faced with very tough challenges. Less than 40% of hypertension patients are aware of their illness, while only one-fourth of them are under proper management. Among those who are under management, 60% are willing to take medicines, while only 50% of them have their blood pressure under control. According to CRI, more than CNY 40 billion is annually spent on hypertension treatment in China. In 2013, market size of antihypertensive prescription drug in China exceeded CNY 20 billion, increased more than 15% YOY. This has shown great potential of Chinese market.
Key Topics Covered:
1 Relevant Concepts of Telmisartan
2 Market Overview of Telmisartan in China
3 Investigation on Sales Value of Telmisartan in China, 2009-2013
4 Investigation on Market Share of Major Telmisartan Manufacturers in China, 2009-2013
5 Investigation on Market Size of Telmisartan by Dosage Form in China, 2009-2013
6 Reference Price of Telmisartan Produced by Different Enterprises in China Hospital Market
7 Analysis on Major Telmisartan Manufacturers in China, 2009-2013
8 Prospect of China Telmisartan Market, 2014-2018
- Boehringer Ingelheim
- Yichang Changjiang Pharmaceutical
- Beijing Double-Crane Pharmaceutical
- Hainan Selection Pharmaceutical
- Wanbang Biopharmaceutical
For more information visit http://www.researchandmarkets.com/research/skgh5l/investigation
Media Contact: Laura Wood , +353-1-481-1716, email@example.com
SOURCE Research and Markets